Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)

13 mars 2020 mis à jour par: University Hospital, Clermont-Ferrand

Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise

The high prevalence of childhood obesity is a major public health issue, worldwide. Childhood obesity is associated with a high risk of cardiovascular events in adulthood, but recent studies also point out the development of cardiovascular complications in childhood or adolescence justifying the need for early detection and appropriate therapeutic management to prevent the development of more severe abnormalities. This project proposes to evaluate the myocardial function in a fine and comprehensive way (longitudinal, circumferential and radial linear deformations, and rotation / torsion mechanics) from the deformation imaging (MRI and high-resolution echocardiography), in obese adolescents following a lifestyle intervention combining diet and physical activity.

Aperçu de l'étude

Statut

Inconnue

Description détaillée

The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.

In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).

Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.

Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.

Type d'étude

Interventionnel

Inscription (Anticipé)

50

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Clermont-Ferrand, France, 63000
        • CHU de Clermont-Ferrand

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

12 ans à 16 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • age between 12 and 16 years old
  • mature (menarche)
  • suitable for physical activity
  • able to give an informative consent
  • affiliated at French insurance company
  • consent from the legal representatives
  • For obese adolescents: BMI greater than the 97th percentile of national curves.
  • For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Exclusion Criteria:

  • Medical or surgical history judged by the investigator as incompatible with the study
  • Drugs that may interfere with the study results
  • Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
  • Smoking
  • Alcohol consumption
  • Intense physical activity in competition

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Obese adolescents
BMI greater than the 97th percentile of national curves. Participants will follow a 3-month lifestyle intervention

Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week.

There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.

Aucune intervention: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
cardiac ectopic fat deposits
Délai: Month 3
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Month 3
cardiac ectopic fat deposits
Délai: Day 0
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
Day 0
cardiac ectopic fat deposits
Délai: Day 0
Quantification of cardiac ectopic fat deposits (volume using MRI)
Day 0
cardiac ectopic fat deposits
Délai: Month 3
Quantification of cardiac ectopic fat deposits (volume using MRI)
Month 3
cardiac ectopic fat deposits
Délai: Month 3
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Month 3
cardiac ectopic fat deposits
Délai: Day 0
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
Day 0
left myocardial regional function
Délai: Month 3
left myocardial regional function (echocardiography)
Month 3
left myocardial regional function
Délai: Month 3
left myocardial regional function (MRI)
Month 3
left myocardial regional function
Délai: Day 0
left myocardial regional function (echocardiography)
Day 0
left myocardial regional function
Délai: Day 0
left myocardial regional function (MRI)
Day 0

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
macrovascularisation
Délai: Day 0
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Day 0
macrovascularisation
Délai: Month 3
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
Month 3
microvascularisation
Délai: Month 3
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Month 3
microvascularisation
Délai: Day 0
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
Day 0
microvascularisation
Délai: Day 0
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Day 0
microvascularisation
Délai: Month 3
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
Month 3
microvascularisation
Délai: Month 3
measure of microvascular perfusion using Iontophoresis procedure
Month 3
microvascularisation
Délai: Day 0
measure of microvascular perfusion using Iontophoresis procedure
Day 0
microvascularisation
Délai: Day 0
measure of microvascular perfusion using flowmotion
Day 0
microvascularisation
Délai: Month 3
measure of microvascular perfusion using flowmotion
Month 3
heart rate variability
Délai: Month 3
measure of heart rate variability using a holter
Month 3
heart rate variability
Délai: Day 0
measure of heart rate variability using a holter
Day 0
skin conductance
Délai: Day 0
measure of skin conductance using Wristband electrodes - Empatica E4
Day 0
skin conductance
Délai: Month 3
measure of skin conductance using Wristband electrodes - Empatica E4
Month 3
Liver steatosis
Délai: Month 3
measure of liver steatosis by MRI
Month 3
Liver steatosis
Délai: Day 0
measure of liver steatosis by MRI
Day 0
Liver steatosis
Délai: Day 0
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Day 0
Liver steatosis
Délai: Month 3
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
Month 3
Liver steatosis
Délai: month 3
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
month 3
Liver steatosis
Délai: Day 0
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
Day 0
Liver fibrosis
Délai: Day 0
measure of liver fibrosis by fibroscanner (liver stiffness)
Day 0
Liver fibrosis
Délai: Month 3
measure of liver fibrosis by fibroscanner (liver stiffness)
Month 3
Liver fibrosis
Délai: Month 3
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Month 3
Liver fibrosis
Délai: Day 0
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
Day 0
blood pressure
Délai: Day0
measure of blood pressure using sphygmomanometer
Day0
blood pressure
Délai: month 3
measure of blood pressure using sphygmomanometer
month 3
Fitness
Délai: Month 3
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Month 3
Fitness
Délai: Day 0
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
Day 0
muscle mass
Délai: Month 3
measure of muscle mass using impedancemeter
Month 3
fat mass
Délai: Month 3
measure of muscle mass using impedancemeter
Month 3
bone structure
Délai: Month 3
measure of muscle mass using impedancemeter
Month 3
muscle mass
Délai: Day 0
measure of muscle mass using impedancemeter
Day 0
fat mass
Délai: Day 0
measure of muscle mass using impedancemeter
Day 0
bone structure
Délai: Day 0
measure of muscle mass using impedancemeter
Day 0
muscle mass
Délai: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
fat mass
Délai: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
bone structure
Délai: Day 0
measure of muscle mass using Densitometry X-ray absorption
Day 0
muscle mass
Délai: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
fat mass
Délai: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
bone structure
Délai: Month 3
measure of muscle mass using Densitometry X-ray absorption
Month 3
muscle mass
Délai: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
fat mass
Délai: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
bone structure
Délai: Month 3
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Month 3
muscle mass
Délai: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
fat mass
Délai: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
bone structure
Délai: Day 0
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
Day 0
muscle mass
Délai: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
fat mass
Délai: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
bone structure
Délai: Day 0
measure of muscle mass using Quantitative ultrasounds (QUS)
Day 0
muscle mass
Délai: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
fat mass
Délai: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
bone structure
Délai: Month 3
measure of muscle mass using Quantitative ultrasounds (QUS)
Month 3
depression
Délai: Day 0
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Day 0
depression
Délai: Month 3
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
Month 3
anxiety
Délai: Day 0
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Day 0
anxiety
Délai: Month 3
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always". It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
Month 3
General health
Délai: Day 0
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Day 0
General health
Délai: Month 3
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
Month 3
Stress
Délai: day 0
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
day 0
Stress
Délai: Month 3
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Fatigue
Délai: Day 0
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Day 0
Fatigue
Délai: Month 3
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
Month 3
Sleep
Délai: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Sleep
Délai: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Burnout
Délai: day 0
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
day 0
Burnout
Délai: Month 3
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
Month 3
Mindfulness
Délai: Day 0
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Day 0
Mindfulness
Délai: Month 3
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
Month 3
Coping
Délai: Day 0
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Day 0
Coping
Délai: Month 3
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
Month 3
Emotions
Délai: Day 0
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Day 0
Emotions
Délai: Month 3
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Month 3
Perception of work
Délai: Day 0
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Day 0
Perception of work
Délai: Month 3
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree). It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
Month 3
Self-efficacy
Délai: Day 0
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Day 0
Self-efficacy
Délai: Month 3
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
Month 3
Alexithymia
Délai: Day 0
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Day 0
Alexithymia
Délai: Month 3
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
Month 3
Illness perception
Délai: Day 0
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Day 0
Illness perception
Délai: Month 3
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
Month 3
Metacognition
Délai: Day 0
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Day 0
Metacognition
Délai: Month 3
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
Month 3
Time perception
Délai: Day 0
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Day 0
Time perception
Délai: Month 3
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale. It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
Month 3
Physical activity
Délai: Day 0
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Day 0
Physical activity
Délai: Month 3
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
Month 3
Life style
Délai: Day 0
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Day 0
Life style
Délai: Month 3
life style is assessed with a questionnaire on coffee consumption, food intake, etc
Month 3
cholesterol
Délai: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
triglycerides
Délai: Day 0
measure by blood analyses to evaluate alloplastic load
Day 0
cholesterol
Délai: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
triglycerides
Délai: Month 3
measure by blood analyses to evaluate alloplastic load
Month 3
Cortisol
Délai: Day 0
hormone measure by blood analyses to evaluate alloplastic load
Day 0
Cortisol
Délai: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
DHEAS
Délai: day 0
hormone measure by blood analyses to evaluate alloplastic load
day 0
DHEAS
Délai: Month 3
hormone measure by blood analyses to evaluate alloplastic load
Month 3
BDNF
Délai: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
BDNF
Délai: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
CRP
Délai: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
pro-inflammatory cytokines
Délai: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
TNF alpha
Délai: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
CRP
Délai: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
pro-inflammatory cytokines
Délai: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
TNF alpha
Délai: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Délai: Month 3
proteins measure by blood analyses to evaluate alloplastic load
Month 3
NPY
Délai: Day 0
proteins measure by blood analyses to evaluate alloplastic load
Day 0
Leptin
Délai: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Leptin
Délai: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
Ghrelin
Délai: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Ghrelin
Délai: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
NPY
Délai: day 0
measure by blood analyses to evaluate appetite regulation
day 0
NPY
Délai: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
adiponectine
Délai: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
adiponectine
Délai: Month 3
measure by blood analyses to evaluate appetite regulation
Month 3
CCK
Délai: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Month 3
Délai: Day 0
measure by blood analyses to evaluate appetite regulation
Day 0
Insulin
Délai: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
Insulin
Délai: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
HbA1c
Délai: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
HbA1c
Délai: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
glucose
Délai: Day 0
measure by blood analyses to evaluate glucid metabolism
Day 0
glucose
Délai: Month 3
measure by blood analyses to evaluate glucid metabolism
Month 3
Albumin
Délai: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
Albumin
Délai: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
transthyretin
Délai: Day 0
measure by blood analyses to evaluate protid metabolism
Day 0
transthyretin
Délai: Month 3
measure by blood analyses to evaluate protid metabolism
Month 3
Homeostasis
Délai: Day 0
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Day 0
Homeostasis
Délai: Month 3
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
Month 3
Osteoresorption
Délai: Day 0
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Day 0
Osteoresorption
Délai: Month 3
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
Month 3
Osteoformation
Délai: Day 0
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Day 0
Osteoformation
Délai: Month 3
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
Month 3
VEGF
Délai: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
VEGF
Délai: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
PAI1
Délai: Day 0
measure by blood analyses to evaluate cardiovascular function
Day 0
PAI1
Délai: Month 3
measure by blood analyses to evaluate cardiovascular function
Month 3
weight
Délai: Day 0
measure of weight in kilograms
Day 0
weight
Délai: Month 3
measure of weight in kilograms
Month 3
waist circumference
Délai: Day 0
measure of waist circumference in centimetres
Day 0
waist circumference
Délai: Month 3
measure of waist circumference in centimetres
Month 3

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Anticipé)

1 septembre 2020

Achèvement primaire (Anticipé)

1 juin 2021

Achèvement de l'étude (Anticipé)

1 juin 2021

Dates d'inscription aux études

Première soumission

10 février 2020

Première soumission répondant aux critères de contrôle qualité

13 mars 2020

Première publication (Réel)

17 mars 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 mars 2020

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 mars 2020

Dernière vérification

1 février 2020

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • RBHP 2019 DUTHEIL
  • 2019-A01804-53 (Autre identifiant: ANSM)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

Indécis

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur 3-month lifestyle intervention

3
S'abonner